News Center

Home page

Peak Report

News reports

The first quarter of 2018 report of Jianfeng Group

Release time:

2021-01-05

公司代码：600668 公司简称：尖峰集团

浙江尖峰集团股份有限公司

2018年第一季度报告正文

一、重要提示

1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。

1.2 公司全体董事出席董事会审议季度报告。

1.3 公司负责人蒋晓萌、主管会计工作负责人兰小龙及会计机构负责人（会计主管人员）吴德富保证季度报告中财务报表的真实、准确、完整。

1.4 本公司第一季度报告未经审计。

二、公司主要财务数据和股东变化

2.1 主要财务数据

单位：元币种：人民币

	本报告期末	上年度末	本报告期末比上年度末增减(%)
总资产	4,366,775,455.41	4,175,730,846.73	4.58
归属于上市公司股东的净资产	2,757,802,176.89	2,627,318,888.65	4.97
	年初至报告期末	上年初至上年报告期末	比上年同期增减(%)
经营活动产生的现金流量净额	13,967,176.23	317,755.25	4,295.58
	年初至报告期末	上年初至上年报告期末	比上年同期增减（%）
营业收入	669,522,008.06	566,846,953.96	18.11
归属于上市公司股东的净利润	104,344,646.12	112,200,485.23	-7.00
归属于上市公司股东的扣除非经常性损益的净利润	98,932,514.65	108,827,872.82	-9.09
加权平均净资产收益率（%）	3.89	4.57	减少0.68个百分点
基本每股收益（元/股）	0.3032	0.3260	-7.00
稀释每股收益（元/股）	0.3032	0.3260	-7.00

非经常性损益项目和金额

单位：元币种：人民币

项目	本期金额	说明
非流动资产处置损益	-25,888.87
越权审批，或无正式批准文件，或偶发性的税收返还、减免
计入当期损益的政府补助，但与公司正常经营业务密切相关，符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外	6,648,601.60
委托他人投资或管理资产的损益	270,624.68
除上述各项之外的其他营业外收入和支出	-166,308.37
少数股东权益影响额（税后）	-196,583.34
所得税影响额	-1,118,314.23
合计	5,412,131.47

2.2 截止报告期末的股东总数、前十名股东、前十名流通股东（或无限售条件股东）持股情况表

单位：股

股东总数（户）			27,298
前十名股东持股情况
股东名称（全称）	期末持股数量	比例(%)	持有有限售条件股份数量	质押或冻结情况			股东性质
				股份状态	数量
金华市通济国有资产投资有限公司	55,564,103	16.15	0	无	0		国有法人
新余中盛恒兴投资管理合伙企业（有限合伙	17,158,922	4.99	0	无	0		未知
新余汇恒瑞投资管理合伙企业(有限合伙)	12,665,208	3.68	0	无	0		未知
香港中央结算有限公司	4,372,091	1.27	0	无	0		未知
刘锦春	3,874,269	1.13	0	无	0		境内自然人
钟以隆	3,584,000	1.04	0	无	0		境内自然人
苏志伟	3,226,848	0.94	0	无	0		境内自然人
王晓红	3,121,943	0.91	0	无	0		境内自然人
骆惠娟	2,726,200	0.79	0	无	0		境内自然人
中国工商银行股份有限公司－南方大数据100指数证券投资基金	2,667,200	0.78	0	无	0		未知
前十名无限售条件股东持股情况
股东名称		持有无限售条件流通股的数量		股份种类及数量
				种类		数量
金华市通济国有资产投资有限公司		55,564,103		人民币普通股		55,564,103
新余中盛恒兴投资管理合伙企业（有限合伙		17,158,922		人民币普通股		17,158,922
新余汇恒瑞投资管理合伙企业(有限合伙)		12,665,208		人民币普通股		12,665,208
香港中央结算有限公司		4,372,091		人民币普通股		4,372,091
刘锦春		3,874,269		人民币普通股		3,874,269
钟以隆		3,584,000		人民币普通股		3,584,000
苏志伟		3,226,848		人民币普通股		3,226,848
王晓红		3,121,943		人民币普通股		3,121,943
骆惠娟		2,726,200		人民币普通股		2,726,200
中国工商银行股份有限公司－南方大数据100指数证券投资基金		2,667,200		人民币普通股		2,667,200
上述股东关联关系或一致行动的说明		本公司第一大股东通济国投与其他上述第2名至第10名无限售条件股东之间不存在关联关系。公司未知其他9名股东之间是否存在关联关系，也未知是否属于《上市公司收购管理办法》规定的一致行动人。
表决权恢复的优先股股东及持股数量的说明		不适用

2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情况表

三、重要事项

3.1 公司主要会计报表项目、财务指标重大变动的情况及原因

				单位：万元
资产负债表项目	期末数	期初数	变动幅度	变动原因
预付款项	9,726.83	4,610.82	110.96%	主要系本报告期子公司预付货款增加所致。
应收股利	2,076.00		100.00%	主要系报告期公司按被投资单位天士力控股集团有限公司2017年度利润分配的股东会决议计入应收的现金股利所致。
其他应收款	1,997.52	1,308.75	52.63%	主要系报告期公司及子公司存出保证金增加所致。
其他流动资产	925.10	1,328.92	-30.39%	主要系报告期子公司抵扣了上年取得的留抵进项税所致。
短期借款	16,800.00	8,900.00	88.76%	主要系报告期公司银行贷款增加所致。
应付职工薪酬	1,279.67	3,627.55	-64.72%	主要系报告期公司及子公司发放上年末计提的年终奖所致。
应付利息	1,579.21	934.17	69.05%	主要系报告期公司计提应付债券利息以及由于银行借款增加相应计提利息增加所致。
应付股利	2,520.16	120.16	1997.38%	主要系报告期子公司股东会决议已宣告发放2017年度现金股利所致。
利润表项目	本期数	上年同期数	变动幅度	变动原因
税金及附加	551.67	336.88	63.76%	主要系报告期子公司应交税费增加所致。
销售费用	10,678.03	4,772.03	123.76%	主要系报告期子公司尖峰药业销售收入的增长和销售模式的调整，公司销售费用中增加了市场推广费和其他支出。
投资收益	1,950.22	6,087.10	-67.96%	主要系报告期公司联营投资单位天士力控股集团有限公司利润大幅减少，公司权益法核算计入投资收益相应减少所致。
其他收益	502.73	0.00	100.00%	主要系本报告期公司按新会计准则要求将与公司日常活动有关的政府补助从“营业外收入”科目转入所致。
营业外收入	171.06	485.84	-64.79%	主要系本报告期公司按新会计准则要求将与公司日常活动有关的政府补助转入“其他收益”项目所致。
营业外支出	27.23	4.66	483.87%	主要系报告期子公司营业外支出增加所致。
所得税费用	3,098.44	1,981.63	56.36%	主要系本报告期子公司实现的利润总额增加相应的所得税费用增加所致。
现金流量表项目
经营活动产生的现金流量净额	1,396.72	31.78	4295.58%	主要系报告期由于公司经营活动现金流入增加所致。
投资活动产生的现金流量净额	-9,823.08	-2,287.17		主要系报告期子公司对外投资及在建项目投入增加所致。
筹资活动产生的现金流量净额	7,779.59	-210.06		主要系报告期公司增加了银行借款所致。

3.2 重要事项进展情况及其影响和解决方案的分析说明

1、2017年2月28日，公司九届10次董事会通过了《关于子公司对外投资的议案》，公司控股子公司尖峰药业拟以增资和股权转让的方式分期对北慧生物进行投资；2018年3月31日，公司披露了对外投资进展情况。上述事项详见2017年3月1日、2018年3月31日本公司披露于上海证券交易所网站（http//:www.sse.com.cn/）的临2017-003《关于子公司对外投资的公告》、临2018-003《关于子公司对外投资的进展公告》。

2、2018年1月19日，本公司十届2次董事会通过了《关于子公司尖峰药业对外投资的议案》，尖峰药业拟投资11132.79万元以收购股份和增资的方式对上海北卡进行投资。投资完成后，上海北卡注册资本由原来的1100万元增加至1755.55万元，其中尖峰药业占55%。上述事项详见2018年1月20日本公司披露于上海证券交易所网站（http//:www.sse.com.cn/）的临2018-002《关于子公司尖峰药业对外投资的公告》。截止报告期末，尖峰药业已经按照协议约定，支付了第一期股权转让款和增资款。目前正在办理资产交接、工商变更登记手续。

3、2017年4月15日，公司九届11次董事会通过了《关于尖峰国贸新建仓库（电商物流园）项目的议案》，批准控股子公司尖峰国贸投资7500万元新建仓库（电商物流园）。2017年6月6日，公司九届13次董事会通过了《关于尖峰国贸仓库出租的议案》，同意尖峰国贸将该新建仓库（电商物流园）的仓库、堆场、停车场等物业出租给上海安能聚创供应链管理有限公司。上述事项详见2017年4月18日、2017年6月7日披露于上海证券交易所网站（http//:www.sse.com.cn/）的临2017-006《九届11次董事会决议公告》和临2017-013《九届13次董事会决议公告》。截止3月底，该项目累计已投入资金3909.65万元。

3.3 报告期内超期未履行完毕的承诺事项

3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明

公司名称	浙江尖峰集团股份有限公司
法定代表人	蒋晓萌
日期	2018年4月27日

发布时间： 2018-04-28

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页